Q-omics provides the consensus-scored CHSY3 profile across patient tissues and cancer cell-line models. CHSY3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CHSY3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CHSY3 RNA expression shows 18,208 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where CHSY3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHSY3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHSY3 survival associations across molecular data types. CHSY3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHSY3 RNA expression–survival associations across cancer types. High CHSY3 expression shows unfavorable associations in MESO, KIRP, STAD, BLCA, UVM and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CHSY3 RNA expression.
This table summarizes CHSY3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CHSY3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHSY3 shows higher tumor expression in KIRC, HNSC, COAD, STAD, BRCA and KIRP. The KIRC box plot shows higher CHSY3 RNA expression in tumor versus normal tissue (log2 FC = +1.604, t-test p < 0.001).
This table shows molecular features associated with CHSY3 in patient tissues and cancer cell lines. In patient samples, CHSY3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHSY3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
